Related Experiment Video
Updated: Aug 21, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Prognostic Factors Analysis in Patients with Hepatocellular Carcinoma Receiving PD-1/PD-L1 Inhibitors
Yubin Pan1, Qijun Li2, Honglin Tang2
1Department of Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, People's Republic of China.
Background:
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced hepatocellular carcinoma (HCC); however, only a minority of patients derive benefits, and reliable biomarkers remain lacking. This study aimed to investigate the associations between peripheral blood markers, clinical characteristics, and outcomes in patients receiving programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors.
Methods:
Clinical and laboratory data from 101 patients treated with PD‑1/PD‑L1 inhibitors were retrospectively analyzed. Optimal cutoff values for continuous variables were determined using the X‑tile. Intergroup comparisons were performed using Pearson's chi-squared or Fisher's exact tests. Univariate Cox regression (SPSS 26.0) was used to identify potential prognostic factors (P<0.1), which were further evaluated by Log rank test and Kaplan-Meier curves. Independent prognostic factors were determined using a multivariate Cox regression analysis.
Results:
The factors associated with efficacy included body mass index, Child‑Pugh class, line of treatment, distant metastasis, bone metastasis, alkaline phosphatase, and total bilirubin. Prognosis‑related indicators included lung metastasis, hemoglobin, absolute neutrophil count, alkaline phosphatase, gamma‑glutamyl transferase, C‑reactive protein, and the best response.
Conclusion:
Based on routine clinical and hematological data, this prognostic study provides an accessible tool for personalized immunotherapy management of HCC.